Completed PHASE2 INTERVENTIONAL 2-arm
NCT07281105
EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Clinical Trial of EG-501 for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
Sponsor: Evergreen Therapeutics, Inc.
Conditions
Cognitive Impairment Neuropsychiatric Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE)
Updated 1 time since 2026 Last updated: Dec 10, 2025 Started: Aug 23, 2018 Primary completion: Aug 12, 2025 Completion: Aug 12, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Cognitive Impairment and Neuropsychiatric Systemic Lupus Erythematosus and is currently completed. Evergreen Therapeutics, Inc. leads this study, which shows 1 recorded version since 2018 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
1 version recorded Completed — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Evergreen Therapeutics, Inc.
- Vanderbilt University Medical Center
Data source: Evergreen Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .